NO20083057L - Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer - Google Patents

Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer

Info

Publication number
NO20083057L
NO20083057L NO20083057A NO20083057A NO20083057L NO 20083057 L NO20083057 L NO 20083057L NO 20083057 A NO20083057 A NO 20083057A NO 20083057 A NO20083057 A NO 20083057A NO 20083057 L NO20083057 L NO 20083057L
Authority
NO
Norway
Prior art keywords
indoles
ligands
sulfonyl substituted
hydroxytryptamine
receptors
Prior art date
Application number
NO20083057A
Other languages
English (en)
Inventor
Yanfang Li
Albert J Robichaud
Ronald Charles Bernotas
Richard Dale Coghlan
Gavin David Heffernan
Robert Emmett Mcdevitt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20083057L publication Critical patent/NO20083057L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I: I som er modulatorer for 5-hydroxtryptamin-6 og 5-hydroksytryptamin-2A reseptorer og som er inhibitorer av norepinefrin gjenopptak. Forbindelsene ifølge oppfinnelsen og farmasøytiske preparater derav, er anvendelige ved behandling av lidelser relatert til eller forbundet med 5-hydroksytryptamin-6 og 5-hydroxtryptamin-2A reseptorer eller med norepinefrin gjenopptak.
NO20083057A 2006-01-13 2008-07-09 Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer NO20083057L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75883306P 2006-01-13 2006-01-13
PCT/US2007/060454 WO2007084841A2 (en) 2006-01-13 2007-01-12 Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors

Publications (1)

Publication Number Publication Date
NO20083057L true NO20083057L (no) 2008-10-03

Family

ID=38179679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083057A NO20083057L (no) 2006-01-13 2008-07-09 Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer

Country Status (16)

Country Link
US (1) US7645752B2 (no)
EP (1) EP1973876A2 (no)
JP (1) JP2009523734A (no)
KR (1) KR20080114688A (no)
CN (1) CN101370775A (no)
AU (1) AU2007206016A1 (no)
BR (1) BRPI0706523A2 (no)
CA (1) CA2636007A1 (no)
CR (1) CR10138A (no)
EC (1) ECSP088620A (no)
IL (1) IL192695A0 (no)
MX (1) MX2008009022A (no)
NO (1) NO20083057L (no)
RU (1) RU2008127501A (no)
WO (1) WO2007084841A2 (no)
ZA (1) ZA200806071B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2273877B1 (en) * 2008-04-23 2014-04-16 Merck Sharp & Dohme Corp. Cyclobutyl sulfones as notch sparing gamma secretase inhibitors
KR102184038B1 (ko) 2008-05-27 2020-11-27 인트라-셀룰라 써래피스, 인코퍼레이티드. 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물
US9000025B2 (en) 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
CN114366741A (zh) 2013-12-03 2022-04-19 细胞内治疗公司 新方法
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
IL260653B2 (en) 2016-01-26 2023-03-01 Intra Cellular Therapies Inc Condensed gamma carbonyls are heterocyclically converted
ES2879888T3 (es) 2016-03-25 2021-11-23 Intra Cellular Therapies Inc Compuestos orgánicos y su uso en el tratamiento o prevención de trastornos del sistema nervioso central
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
BR112019019875A2 (pt) 2017-03-24 2020-04-22 Intra Cellular Therapies Inc novas composições e métodos
CA3069699A1 (en) * 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. Analogs of cyclobenzaprine and amitryptilene
BR112020001666A2 (pt) 2017-07-26 2020-07-21 Intra-Cellular Therapies, Inc. compostos orgânicos
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Transformed histories of gamma-carbolines fused with heterocyclics, pharmaceutical preparations containing them and their use for treatment
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
US10695345B2 (en) 2018-08-31 2020-06-30 Intra-Cellular Therapies, Inc. Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
PL3860998T3 (pl) 2018-10-05 2024-06-17 Annapurna Bio Inc. Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338625C (en) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
JP2536789B2 (ja) 1990-03-05 1996-09-18 信越化学工業株式会社 窯業系外壁材組成物
US5132319A (en) * 1991-03-28 1992-07-21 Merck Frosst Canada, Inc. 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
JPH06509087A (ja) 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
US5273980A (en) * 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5308850A (en) 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
AU3488693A (en) 1992-02-13 1993-09-03 Merck Frosst Canada Inc. (Azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis
TW226019B (no) 1992-03-23 1994-07-01 Sankyo Co
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
MX9304801A (es) * 1992-08-06 1997-06-28 Warner Lambert Co 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales.
JP3257054B2 (ja) 1992-08-20 2002-02-18 セイコーエプソン株式会社 液滴吐出装置とその駆動方法
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
US5418242A (en) * 1993-05-18 1995-05-23 Laboratoires Upsa Piperidinylthioindole derivatives, their methods of preparation and pharmaceutical compositions in which they are present, useful especially as analgesics
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
JP2840181B2 (ja) 1993-08-20 1998-12-24 大日本スクリーン製造株式会社 多層膜試料の膜厚測定方法
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0763035A4 (en) 1994-06-09 1997-10-01 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) * 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
DE19527705A1 (de) 1995-07-28 1997-01-30 Teves Gmbh Alfred Hydraulische Kraftfahrzeugbremsanlage mit Radschlupfregelung
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
GB9602028D0 (en) * 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
GB2309969B (en) 1996-02-01 2000-08-09 Amersham Int Plc Nucleoside analogues
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
AU3261097A (en) 1996-06-21 1998-01-14 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
ATE266636T1 (de) * 1997-09-09 2004-05-15 Bristol Myers Squibb Pharma Co Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
BR9813926A (pt) 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
SK6262000A3 (en) 1997-11-04 2002-03-05 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
WO1999043654A2 (en) 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1071661A4 (en) 1998-04-17 2001-08-22 Lilly Co Eli METHOD FOR PRODUCING 4-HYDROXYINDOL, INDAZOL AND CARBAZOL COMPOUNDS
ES2262072T3 (es) * 1998-04-28 2006-11-16 Elbion Ag Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4.
DE19818964A1 (de) 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
JP2000198734A (ja) 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AUPP971499A0 (en) * 1999-04-12 1999-05-06 Opentec Pty. Limited On-line electoral system
CO5190665A1 (es) 1999-06-23 2002-08-29 Smithkline Beecham Corp Compuestos de indol
WO2001005758A2 (en) 1999-07-15 2001-01-25 Nps Allelix Corp. Indoles and indazoles for the treatment of migraine
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
US20030176421A1 (en) * 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
AT500496B8 (de) * 2000-05-16 2007-02-15 Tulln Zuckerforschung Gmbh Verfahren zur hemmung von thermophilen mikroorganismen in zuckerhaltigen medien
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
WO2002051849A1 (fr) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs cdk4
US6754642B2 (en) * 2001-05-31 2004-06-22 Contentguard Holdings, Inc. Method and apparatus for dynamically assigning usage rights to digital works
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
AU2002303084B2 (en) 2001-02-02 2006-05-25 Pharmacopiea, Inc. 3,4-di-substituted cyclobutene-1, 2 -diones as CXC chemokine receptor antagonists
MXPA03007853A (es) * 2001-03-01 2004-05-24 Pharmasset Ltd Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.
WO2002079198A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
WO2002083126A1 (en) * 2001-04-11 2002-10-24 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
IL158997A0 (en) * 2001-06-07 2004-05-12 Hoffmann La Roche New indole derivatives with 5-ht6 receptor affinity
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
US20040242589A1 (en) * 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
EP1453515A4 (en) * 2001-11-09 2006-11-29 Scios Inc METHOD FOR TREATING CYSTIC FIBROSIS
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
EP1545510A4 (en) * 2002-08-07 2006-11-15 Idenix Cayman Ltd SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV
PL376479A1 (en) * 2002-10-18 2005-12-27 F.Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
KR20050072812A (ko) * 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
TWI284124B (en) * 2002-12-03 2007-07-21 Hoffmann La Roche Aminoalkoxyindoles
CN100482662C (zh) * 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
CN100422171C (zh) * 2003-02-14 2008-10-01 惠氏公司 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑
JP4925594B2 (ja) 2005-03-22 2012-04-25 ダイハツ工業株式会社 燃料電池装置
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2629962A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles

Also Published As

Publication number Publication date
WO2007084841A3 (en) 2007-09-13
CN101370775A (zh) 2009-02-18
AU2007206016A1 (en) 2007-07-26
CR10138A (es) 2008-10-03
US20070203120A1 (en) 2007-08-30
MX2008009022A (es) 2008-09-24
ECSP088620A (es) 2008-08-29
BRPI0706523A2 (pt) 2011-01-04
JP2009523734A (ja) 2009-06-25
KR20080114688A (ko) 2008-12-31
EP1973876A2 (en) 2008-10-01
ZA200806071B (en) 2009-04-29
WO2007084841A2 (en) 2007-07-26
IL192695A0 (en) 2009-02-11
US7645752B2 (en) 2010-01-12
RU2008127501A (ru) 2010-02-20
CA2636007A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
EA200970156A1 (ru) Пиридизиноновые производные
NO20085031L (no) Benzimidazolmodulatorer av VR1
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
NO20084850L (no) MGLUR5 modulatorer I
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
NO20065678L (no) 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
MA32508B1 (fr) Composes organiques
EA201170772A1 (ru) Органические соединения
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
ATE421518T1 (de) Dihydrochinazolinone als 5ht-modulatoren
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
NO20091626L (no) MGLUR5-modulatorer
EA200970067A1 (ru) Агонисты ep2
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application